Nuveen’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-93,961
| Closed | -$1.23M | – | 3232 |
|
|
2025
Q4 | $1.23M | Sell |
93,961
-266,070
| -74% | -$3.18M | ﹤0.01% | 2514 |
|
|
2025
Q3 | $2.62M | Sell |
360,031
-9,359
| -3% | -$63.3K | ﹤0.01% | 2189 |
|
|
2025
Q2 | $1.98M | Buy |
369,390
+265,873
| +257% | +$1.29M | ﹤0.01% | 2306 |
|
|
2025
Q1 | $553K | Hold |
103,517
| – | – | ﹤0.01% | 2876 |
|
|
2024
Q4 | $925K | Hold |
103,517
| – | – | ﹤0.01% | 2744 |
|
|
2024
Q3 | $1.14M | Sell |
103,517
-194,520
| -65% | -$2.16M | ﹤0.01% | 2698 |
|
|
2024
Q2 | $2.71M | Buy |
298,037
+90,840
| +44% | +$887K | ﹤0.01% | 2232 |
|
|
2024
Q1 | $2.92M | Buy |
207,197
+105,031
| +103% | +$1.31M | ﹤0.01% | 2223 |
|
|
2023
Q4 | $785K | Buy |
102,166
+2,290
| +2% | +$12.7K | ﹤0.01% | 2835 |
|
|
2023
Q3 | $745K | Buy |
99,876
+8,485
| +9% | +$72.4K | ﹤0.01% | 2694 |
|
|
2023
Q2 | $761K | Buy |
+91,391
| New | +$1.05M | ﹤0.01% | 2775 |
|
|
2021
Q2 | – | Sell |
-13,933
| Closed | -$241K | – | 3367 |
|
|
2021
Q1 | $241K | Buy |
13,933
+920
| +7% | +$16.6K | ﹤0.01% | 3205 |
|
|
2020
Q4 | $167K | Buy |
13,013
+1,022
| +9% | +$18.2K | ﹤0.01% | 3215 |
|
|
2020
Q3 | $445K | Sell |
11,991
-6,070
| -34% | -$241K | ﹤0.01% | 2985 |
|
|
2020
Q2 | $697K | Buy |
+18,061
| New | +$643K | ﹤0.01% | 2779 |
|
Nuveen's ATXS Position: Q1 2026 in Review
Nuveen sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 93,961 shares — an estimated $1.23M sold.
Nuveen first reported a position in ATXS in Q2 2020 and held it in 15 quarters. The position peaked at $2.92M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Nuveen reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Nuveen sold 93,961 Astria Therapeutics shares in Q1 2026, an estimated $1.23M.
- Nuveen first reported a position in Astria Therapeutics in Q2 2020 and held it in 15 quarters.
- Nuveen's Astria Therapeutics position peaked at $2.92M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.